Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - Results at six months after transplantation

Howard J. Eisen, Robert E. Hobbs, Stacy F. Davis, Guenther Laufer, Donna M. Mancini, Dale G. Renlund, Hannah Valantine, Hector Ventura, Jean Luc Vachiery, Robert C. Bourge, Charles C. Canver, Michel Carrier, Maria Rosa Costanzo, Jack Copeland, Georges Dureau, O. Howard Frazier, Richard Dorent, Paul J. Hauptman, Catherine Kells, Roy MastersJean Luc Michaud, Irvin Paradis, Andrew Smith, Johan Vanhaecke, Gilles Feutren, Diane Turkin, Bernd Mellein, Edgar A. Mueller

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Background. The introduction of cyclosporine has resulted in significant improvement in the survival of cardiac allograft recipients due to decreased mortality from infection and rejection. The original oil-based cyclosporine formulation exhibits variable and unpredictable bioavailability that correlates with an increased incidence of acute and chronic rejection in those patients in whom this is most pronounced. The primary objectives of this prospective, multicenter, randomized, double-blind study in cardiac transplant patients were: to compare the efficacy of cyclosporine microemulsion (CsA-NL) with oil-based cyclosporine (CsA-SM) as measured by cardiac allograft and recipient survival and the incidence and severity of acute rejection episodes; and to assess the safety and tolerability of CsA-NL compared with CsA-SM in this population. This report represents the analysis of results 6 months after transplantation. Methods. A total of 380 patients undergoing their first cardiac transplant at 24 centers in the United States, Canada, and Europe were enrolled in this double-blind, randomized trial examining the safety and efficacy of CsA-NL versus CsA-SM. Rejection was diagnosed using endomyocardial biopsy and were graded according to standardized criteria of the International Society of Heart and Lung Transplantation (ISHLT). Clinical parameters were monitored during the study. Survival and freedom from were used for analysis as was Fisher's exact test for comparisons between groups. Results. At 6 months after transplantation, allograft and patient survival were the same for both groups. The frequency of ISHLT grade 3A or greater episodes in the two groups was identical. Fewer CsA-NL patients (5.9%) required antilymphocyte antibody (ATG or OKT-3) therapy for rejection compared with the CsA-SM-treated patients (14.1%, P=0.01). Females with ISHLT rejection grade≥3A treated with CsA-NL had a 46% lower incidence of rejection compared with the CsA-SM-treated group (31.3% vs. 57.6%, P=0.032). Fewer infections were seen in the CsA-NL. With the exception of baseline and 1 week posttransplant creatinines which were higher in the CsA-NL group, the overall creatinine was not significantly different between the two groups. Conclusions. This multicenter, randomized study of cardiac transplant recipients documented less severe rejection (in particular those requiring antibody therapy) and a lower incidence of infection in CsA- NL-treated patients. Results from the female subgroup analysis suggest that the improved bioavailability of CsA-NL might reduce the frequency of rejection episodes in female patients. The use of CsA-NL was not associated with an increased risk of adverse events.

Original languageEnglish (US)
Pages (from-to)663-671
Number of pages9
JournalTransplantation
Volume68
Issue number5
DOIs
StatePublished - Sep 15 1999

All Science Journal Classification (ASJC) codes

  • Transplantation

Fingerprint

Dive into the research topics of 'Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - Results at six months after transplantation'. Together they form a unique fingerprint.

Cite this